Janux Therapeutics (JANX) stock rose 7.1% after the company reported narrower net losses and an improved earnings profile. Earnings improvement drives short-term stock gain but does not signal major strategic or competitive shifts.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | 1 | 1 | 1 | 6 | — | — | — | 1 | 1 | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2025 | ‡‡‡ |
|
| 2024 | ‡‡‡ |
|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 344.03 | 1,025.17 | 966.57 | 970.91 |
| Receivables | — | — | — | 0.15 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 349.24 | 1,033.67 | 975.89 | 983.34 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 2.42 | 4.03 | 4.97 | 3.02 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 13.03 | 17.46 | 25.00 | 60.15 |
| 10y | 5y | 3y | |
| Sales | — | — | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 3.73 | 10.27 | — | — |
—
|
| ’25 | — | — | 10.00 | — |
10.00
|
| ’24 | 1.25 | 8.90 | 0.44 | 0.00 |
10.59
|
| ’23 | 2.05 | 1.06 | 2.52 | 2.46 |
8.08
|
| ’22 | 1.59 | 2.37 | 1.81 | 2.85 |
8.61
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (12.34) | 12.48 | — | — |
—
|
| ’25 | (17.02) | (23.81) | (12.86) | (28.54) |
(82.23)
|
| ’24 | (14.84) | (10.02) | (2.23) | (16.72) |
(43.81)
|
| ’23 | (13.91) | (15.05) | (11.71) | (9.90) |
(50.57)
|
| ’22 | (11.52) | (6.07) | (13.41) | (11.91) |
(42.92)
|
| ’21 | 5.56 | (6.20) | (5.85) | (10.48) |
(16.98)
|
| ’20 | (0.88) | (1.66) | (1.08) | (1.63) |
(4.37)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (12.61) | 12.28 | — | — |
—
|
| ’25 | (17.39) | (24.29) | (12.95) | (28.65) |
(83.28)
|
| ’24 | (15.03) | (10.12) | (2.26) | (16.77) |
(44.17)
|
| ’23 | (14.20) | (15.63) | (12.18) | (10.42) |
(52.42)
|
| ’22 | (12.49) | (6.97) | (15.93) | (13.97) |
(49.37)
|
| ’21 | 5.41 | (6.28) | (5.93) | (11.65) |
(18.46)
|
| ’20 | (0.88) | (1.66) | (1.08) | (1.63) |
(4.37)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.39) | (0.35) | — | — |
—
|
| ’25 | (0.38) | (0.55) | (0.39) | (0.51) |
(1.83)
|
| ’24 | (0.30) | (0.11) | (0.51) | (0.36) |
(1.28)
|
| ’23 | (0.42) | (0.42) | (0.25) | (0.25) |
(1.32)
|
| ’22 | (0.32) | (0.41) | (0.40) | (0.39) |
(1.52)
|
| ’21 | (0.05) | (0.62) | (0.26) | (0.33) |
(1.39)
|
| ’20 | (0.03) | (0.06) | (0.03) | — |
(0.16)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | ‡‡‡‡‡ | 9.39 | 5.65 | 7.79 | 13.62 | — | — | — |
Low Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 20.85 | 23.64 | 71.71 | 61.59 | — | — | — |
High Price
|
| — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | 60 | 64 | 81 | 109 | — | — | — |
Employees
|
| — | — | — | — | ‡‡‡ | ‡‡‡‡‡ | 0.14 | 0.13 | 0.13 | 0.09 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | ‡‡‡‡‡ | 8.61 | 8.08 | 10.59 | 10.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 100.00% | 100.00% | 100.00% | 100.00% | — | — | — |
Gross Margin
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (63.06) | (58.29) | (68.99) | (113.62) | — | — | — |
EBT
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (732.22%) | (721.18%) | (651.62%) | (1,136.25%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (63.06) | (58.29) | (68.99) | (113.62) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.34) | (5.73) | (8.52) | (15.54) | — | — | — |
Depreciation
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 0.21 | 0.18 | 0.20 | 0.16 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | — | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.52) | (1.32) | (1.28) | (1.83) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.03) | (1.15) | (0.82) | (1.33) | ‡‡‡‡‡ | — | — |
Cash Flow/Sh
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (0.16) | (0.04) | (0.01) | (0.02) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.19) | (1.19) | (0.82) | (1.34) | — | — | — |
Free CF/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.73 | 7.82 | 19.03 | 15.44 | — | — | — |
Book Value/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 41.47 | 44.02 | 53.75 | 61.97 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | ‡‡‡‡‡ | 67.51 | 60.01 | 271.80 | 44.23 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | ‡‡‡‡‡ | 1.81 | 1.41 | 2.81 | 0.89 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | ‡‡‡‡‡ | 32.48 | 20.53 | 177.33 | (4.47) | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | ‡‡‡‡‡ | (5.67) | (3.16) | (42.50) | 1.04 | — | — | — |
EV/FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (42.92) | (50.57) | (43.81) | (82.23) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | — | — | ‡‡‡‡‡ | (6.44) | (1.85) | (0.36) | (1.04) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (49.37) | (52.42) | (44.17) | (83.28) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 315.93 | 336.21 | 1,016.21 | 950.89 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 25.31 | — | — | — | — | — | — |
Total Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (301.71) | (344.03) | (1,025.17) | (966.57) | — | — | — |
Net Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 320.74 | 344.35 | 1,022.78 | 956.82 | — | — | — |
Sh' Equity
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (16.96%) | (15.66%) | (9.57%) | (11.02%) | — | — | — |
ROA
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | (220.36%) | (14,209.31%) | 0.00% | 0.00% | — | — | — |
ROIC
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (18.36%) | (17.53%) | (10.09%) | (11.48%) | — | — | — |
ROE
|
Janux Therapeutics (JANX) is a high-stakes biotech bet on next-gen T-cell engagers targeting tough solid tumors like prostate and EGFR-driven cancers. As of early 2026, the stock lurks near lows, just 9% above the gloomiest analyst target but a massive 307% below the average and over 1,000% off the high—screaming high-risk, high-reward in a sector battered by post-IPO funding droughts and rate hikes. Yet, with revenue CAGR at 69% from partnerships like Gilead’s $1.2B deal, a fortress balance sheet boasting $1B+ in net cash for a 4-5 year runway, and escalating losses typical of clinical ramp-ups, JANX has insider conviction: a director’s $25M blockbuster buy in 2025 dwarfs minor sells.
The stock’s wild ride—from $71 peaks on Phase 1 data to 82% drawdowns—mirrors biotech whiplash, fueled by trial hype and macro fears, with valuations like 272x PS screaming future growth bets. Projections show near-term pain (revenue plunging 82% in 2026 amid -$250M losses), but Phase 2 readouts for leads JANX007/008 and potential buyouts could spark 300%+ upside to average targets, especially with Fed cuts thawing M&A.
This speculative gem trades at a discount to its cash pile and pipeline promise amid oncology booms, but trial flops or dilution loom. Dive into the full analysis for historicals, metrics, and why savvy insiders are loading up—could JANX be your biotech breakout?
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.